MAPS 2025

MAPS 2025 Decoded: The Medical Affairs Playbook for Successful Drug Launches

At the MAPS Americas 2025 conference in New Orleans, one of the pivotal discussions centered around preparing for drug launches in the current pharmaceutical landscape. While many important topics were covered, a critical element that was notably missing from the discussion was the need for a strategic north star—a guiding philosophy that ensures all tactical…...
Read More

Top Stories

DIA MASC 2025

Medical Affairs 2.0: GenAI as the Catalyst for

Digital and AI were hot topics underpinning many of the...
Biopharma 2025 Trends

Biopharma Trends 2025: 3 Things to Know Right Now

The global business climate is ever-evolving, and 2025 looks...

The Paradigm Shift from Traditional Scientific

In the rapidly evolving biopharma landscape, the approach to...
Simplifying the omnichannel approach to publication planning

Simplifying the Omnichannel Publication Planning Approach

While the pharma and publication industries use multiple channels like emails, social media, conferences, and...
Building public trust in pharma

3 Factors That Will Help Pharma Build Public Trust

Pharma must engage with patients at all levels to build public trust...
Image for the graphical abstracts blog by Cactus Life Sciences

Reel Your Audience in with a Visual Abstract

Graphical abstracts allow room for science communication to be reimagined in a range of creative...
Vaccine

Role of Scientific Communication and Medical Professionals in Combating Vaccine Hesitancy

Read an insightful discussion from the latest ISMPP conference on how science communication and medical...
UX design for scientific writing

Future of Scientific Writing and Journal Articles with UX Design

Take a look at some ideas and examples on how user experience design can be...
ISMPP full report image

17th Virtual Annual Meeting of ISMPP: A Summarized Report

Session summaries from the latest ISMPP conference on trust and equity in science, digital transformation...

Learn more ABOUT our company.